Capricor Therapeutics, Inc.
Capricor Therapeutics, Inc. (Nasdaq: CAPR) is a biotechnology company developing cell- and exosome-based therapies for Duchenne muscular dystrophy (DMD) and other diseases. Its lead candidate, Deramiocel, is a cell therapy made from cardiosphere-derived cells and intended to address skeletal and cardiac muscle… From the company’s description.
In fiscal 2025, Capricor Therapeutics, Inc. reported a net loss of $105.04M. Operations used $69.81M in cash.
Margins and return on equity change in ; everything else in percent. Fewer shares and less debt are shown plainly, not as bad news — it depends what you make of buybacks. Dotted labels explain each measure. is shown separately from the annual figures.
What Capricor Therapeutics, Inc. does
In the company’s own words
Capricor Therapeutics, Inc. (Nasdaq: CAPR) is a biotechnology company developing cell- and exosome-based therapies for Duchenne muscular dystrophy (DMD) and other diseases. Its lead candidate, Deramiocel, is a cell therapy made from cardiosphere-derived cells and intended to address skeletal and cardiac muscle complications of DMD; its U.S. biologics license application is under FDA review. The company has no products approved for commercial sale. Capricor is also developing Deramiocel for Becker muscular dystrophy and engineered exosome programs, including the StealthX vaccine candidate for SARS-CoV-2, which is in a Phase 1 study, and exploratory exosome-based therapeutic delivery approaches. It operates through these research and development programs rather than separately reported business segments. Capricor conducts clinical development and manufacturing, with Nippon Shinyaku holding exclusive distribution rights for Deramiocel in the United States and Japan. In 2025, the company reported two facilities for Deramiocel manufacturing. Its website is https://capricor.com/.
Company details
- Sector
- Health Care
- Industry (SIC)
- Pharmaceutical Preparations
- Headquarters
- SAN DIEGO, CA
- Fiscal year end
- December
- CIK
- 1133869
- SIC
- 2834
Financial performance, year by year
Fiscal 2011–2025 · USDThe full income statement, balance sheet and cash flow for each of these years — every figure traceable to its filing — is on the Financials tab with a free account.
Who owns Capricor Therapeutics, Inc. — and what changed
Funds as of 2026Q2 · superinvestors as of 2026-06-30
Largest fund holders · Capricor Therapeutics, Inc.’s weight in each
Fund ownership is a floor, not a census — pensions, insurers and people holding shares directly are not visible here.
Fund ownership counts N-PORT filers only, so it is a floor rather than a census — pensions, insurers and direct holders are not visible here, and the remainder is not “held by individuals”.
Every fund and institutional holder, quarter by quarter, is on the Ownership tab with a free account.
Recent filings
All filings →Each filing opens into its own statements and disclosures here.
Put this business in context.
Compare this company with peers, find it in your funds and follow its financial history with your connected AI:
- “How do Capricor Therapeutics, Inc. and its peers compare on margins and cash generation over ten years?”
- “Where did five years of Capricor Therapeutics, Inc.'s earnings go — cash, debt, buybacks, reinvestment?”
- “What changed in Capricor Therapeutics, Inc.'s last four quarterly filings that the numbers alone won't show?”